isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin

摘要

isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to at least one small alk molecule kinase inhibitor, to evaluate a biological sample for an Aβ inhibitor resistance mutation lk, to diagnose a cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce the expression of an alkali resistant mutant, to treat a cancer associated with aberrant alkaline activity that is resistant to at least one small molecule alkaline kinase inhibitor, treating cancer associated with aberrant alkaline activity that is resistant to pf-02341066, identifying an agent capable of inhibiting the kinase activity of a mutant resistant to alk or alk fusion protein. Compositions and methods for diagnosing and treating cancer that is resistant to at least one anaplastic lymphoma kinase (alk) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within alk that confer resistance to at least one alk inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis and / or treatment of diseases associated with activity. aberrant alkali, more particularly those which are resistant to at least one alkaline kinase inhibitor. Methods and compositions are also provided for identifying agents that may inhibit kinase activity and / or reduce the expression level of alk resistance mutants.